Published in Pharm Res on March 01, 1988
Prodrug approaches for CNS delivery. AAPS J (2008) 1.17
"All in the mind"? Brain-targeting chemical delivery system of 17β-estradiol (Estredox) produces significant uterotrophic side effect. Pharm Anal Acta (2012) 0.82
Chronic inhibition of hypothalamic-pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17 beta in female rats. Neuroendocrinology (1989) 0.79
Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci (1996) 3.83
Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther (1998) 2.19
Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg (1997) 2.01
Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol (2006) 1.82
Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol (2001) 1.57
The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care (2000) 1.54
AUIC--a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother (1996) 1.51
Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci (1992) 1.45
The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol (1989) 1.43
Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J (2001) 1.43
N-Halo derivatives VI: Microbiological and chemical evaluations of 3-chloro-2-oxazolidinones. J Pharm Sci (1976) 1.38
Microdialysis in peripheral tissues. Adv Drug Deliv Rev (2000) 1.35
Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol (2001) 1.34
Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther (1986) 1.32
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther (1997) 1.25
Properties of a new chloramine disinfectant and detoxicant. Poult Sci (1982) 1.23
Antimicrobial activity of N-chloramine compounds. J Pharm Sci (1980) 1.20
N-Halo derivatives V: Comparative antimicrobial activity of soft N-chloramine systems. J Pharm Sci (1976) 1.19
Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol (1998) 1.17
Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet (1998) 1.17
Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol (1997) 1.16
Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother (2001) 1.04
Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung (1996) 1.04
Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm Res (2001) 1.02
Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J Med Chem (1980) 0.99
A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother (2000) 0.99
Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res (1996) 0.99
Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother (1998) 0.98
Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol (1996) 0.98
Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther (1999) 0.97
Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J Pharm Sci (1997) 0.97
A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J Pharm Biomed Anal (2000) 0.95
Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther (1998) 0.94
Enhanced delivery of ganciclovir to the brain through the use of redox targeting. Antimicrob Agents Chemother (1994) 0.94
Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther (1999) 0.94
Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. Phytomedicine (2005) 0.94
Octanol-water partition: searching for predictive models. Curr Med Chem (1998) 0.93
Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther (1997) 0.93
Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol (1997) 0.93
Photoelectron spectra, hydrolytic stability, and antimicrobial activity of N-chlorinated piperidines. J Pharm Sci (1974) 0.93
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm (1999) 0.92
Determination of free extracellular concentrations of piperacillin by microdialysis. J Pharm Sci (1996) 0.92
Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res (1991) 0.92
An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci (2000) 0.92
The use of human nasal in vitro cell systems during drug discovery and development. Toxicol In Vitro (2005) 0.92
Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol (1985) 0.92
Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem (1992) 0.90
Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J Med Chem (1996) 0.90
Site-specific, sustained release of drugs to the brain. Science (1981) 0.89
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol (2001) 0.89
Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. J Pharm Sci (2007) 0.89
Resumption with clonidine of pulsatile LH release following acute norepinephrine depletion in ovariectomized rats. Neuroendocrinology (1982) 0.88
Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Int J Clin Pharmacol Ther (2005) 0.88
Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol (1991) 0.88
Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids. J Chromatogr (1985) 0.88
Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit (1986) 0.87
Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques. Steroids (1996) 0.87
Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev (2000) 0.87
Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther (1985) 0.87
Rational development of a soluble prodrug of a cytotoxic nucleoside: preparation and properties of arabinosyladenine 5'-formate. J Pharm Sci (1975) 0.87
Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm Res (1991) 0.86
Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol (1997) 0.86
Problems of delivery of drugs to the brain. Pharmacol Ther (1982) 0.86
Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(epsilon-caprolactone-co-trimethylenecarbonate) polymeric micelles. Int J Pharm (2006) 0.86
Soft drugs: principles and methods for the design of safe drugs. Med Res Rev (1984) 0.85
Brain, blood, and cerebrospinal fluid distribution of a zidovudine chemical delivery system in rabbits. J Pharm Sci (1991) 0.85
Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol (1999) 0.85
Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos (1987) 0.85
Desensitization of brain opiate receptor mechanisms by gonadal steroid treatments that stimulate luteinizing hormone secretion. Endocrinology (1988) 0.85
Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue. J Pharm Sci (1996) 0.84
HPLC determination of dexamethasone in human plasma and its application to an in vitro release study from endovascular stents. Pharmazie (2006) 0.84
Simultaneous assay of propranolol, diltiazem and metabolites of diltiazem in human plasma by liquid chromatography. J Pharm Biomed Anal (1990) 0.84
Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection (2005) 0.84
Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters. Pharmazie (2002) 0.84
Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol (1997) 0.84
Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther (1999) 0.84
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res (1995) 0.84
Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl-beta-cyclodextrin. Pharm Res (1991) 0.83
Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther (2011) 0.83
Local treatment of respiratory infections with antibiotics. Drug Intell Clin Pharm (1987) 0.83
Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem (1999) 0.83
Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol (1997) 0.83
A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. J Pharmacokinet Pharmacodyn (2007) 0.83
Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size-based model. Proteins (1998) 0.83
Transfer of phosphatidylcholine facilitated by a component of human plasma. Biochim Biophys Acta (1978) 0.83
Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol (1992) 0.82
Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol (1991) 0.82
Effect of choline esters and oleic acid on the penetration of acyclovir, estradiol, hydrocortisone, nitroglycerin, retinoic acid and trifluorothymidine across hairless mouse skin in vitro. Acta Pharm Nord (1989) 0.82
Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob Agents Chemother (1997) 0.82
A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine. J Forensic Sci (1988) 0.82
Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. Pharm Res (2000) 0.82
Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues. J Med Chem (2000) 0.81
Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). J Clin Pharmacol (2001) 0.81
Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie (2002) 0.81
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol (1997) 0.81